

WORKSHOP ALFASIGMA

FRIDAY, 25 JUNE 2021

16:30-17:30 Industry Session – Alfasigma

Venous patients: Facing the current clinical challenges

Chair: A. Nicolaides (Cyprus), S. Kakkos (Greece)

16:30 New perspectives on pathophysiology and investigation

A. Nicolaides (Cyprus)

16:50 Sulodexide in early stages of COVID-19 patients: A randomised controlled trial

A. Gonzalez Ochoa (Mexico)

17:10 Challenges in the treatment of symptomatic CVD patients in our daily practice

A. Mansilha (Portugal)

HIGHLIGHTS FROM THE SCIENTIFIC PROGRAMME

THURSDAY, 24 JUNE 2021

09:10 **Sulodexide may accelerate and promote deep vein thrombosis resolution**

Aldrett Lee, Erasto (Mexico); Frati Munari, Alberto (Mexico)

SATURDAY, 26 JUNE 2021

10:10 **Reducing hyperpigmentation after sclerotherapy (RHYAS) study: results of a multicenter, controlled, randomized clinical trial.**

*Gonzalez Ochoa, Alejandro (Mex); Carrillo Joaquin (Mex);
Manriquez Diana (Mex); Nuricumbo Alejandro (Mex).*

Paper P14 SULODEXIDE IMPROVES CAPILLARY BLOOD FLOW AND THE QUALITY OF LIFE IN PATIENTS WITH RAYNAUD SYNDROME - *Juszynski, Michal; Madycki, Grzegorz (POL)*

Paper P25 SULODEXIDE COMBINED WITH COMPRESSION IMPROVES SYMPTOMS IN PATIENTS WITH CEAP STAGES C0S AND C1S - *Lecuona, Nora (MEX)*

Paper P30 EFFECTS ON INFLAMMATION AND TISSUE PERFUSION OF DIFERENT ROUTES OF ADMINISTRATION AND DOSES OF SULODEXIDE ON AN ANIMAL MODEL OF LOW FLOW AND HIGH PRESSURE IN VEINS - *Leal IB, Cyrino FZGA, Souza MGC and Bouskela E (BRA)*